Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Modongo, Chawangwa ^a,b,c   Sobota, Rafal S ^d   Kesenogile, Boikobo ^c,e   Ncube, Ronald ^f   Sirugo, Giorgio ^g   Williams, Scott M ^d   Zetola, Nicola M ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOTSWANA UPENN PARTNERSHIP   (Botswana)

^c UNIVERSITY OF BOTSWANA   (Botswana)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e PRINCESS MARINA HOSPITAL   (Botswana)

^f Department of HIV AIDS Prevention and Care   (Botswana)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Amikacin; Aminoglycosides; Hearing loss; HIV; Multi drug resistant tuberculosis

Indexed keywords

AMIKACIN;

ARTICLE; AUDIOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84928748664     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-542     Document Type: Article

References (44)

1. Caminero JA: Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis. In 68 boulevard St Michel, 75006 Paris, Franc: International Union Against Tuberculosis and Lung Disease (The Union); 2013.
2. Organization WH: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. In Geneva: WHO/HTM/TB/2011.6; 2011.
3. Health FJCNTCaCDoP: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. In 2nd edition. ; 2008.
4. World Health O: Multidrug-resistant tuberculosis (MDR-TB) October 2013 Update. In 2013.
5. Program BNT: National Tuberculosis Manual. In 7th edition. Ministry of Health: Gaborone; 2011.
6. Pandya A, Xia X, Radnaabazar J, Batsuuri J, Dangaansuren B, Fischel-Ghodsian N, Nance WE: Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. J Med Genet 1997, 34(2):169-172.
7. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, Wendt KA, Nelson RA, Arnos KS, Falk RE: Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997, 18(3):173-178.
8. Fischel-Ghodsian N, Prezant TR, Fournier P, Stewart IA, Maw M: Mitochondrial mutation associated with nonsyndromic deafness. Am J Otolaryngol 1995, 16(6):403-408.
9. Fischel-Ghodsian N, Prezant TR, Bu X, Oztas S: Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. Am J Otolaryngol 1993, 14(6):399-403.
10. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, Lietman PS: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980, 302(20):1106-1109.
11. Smith CR, Lipsky JJ, Lietman PS: Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother 1979, 15(6):780-782.
12. Moore RD, Smith CR, Lietman PS: The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984, 149(3):443-448.
13. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984, 100(3):352-357.
14. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D: Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004, 38(11):1538-1544.
15. Matz GJ: Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993, 26(5):705-712.
16. Fausti SA, Frey RH, Henry JA, Olson DJ, Schaffer HI: Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J Am Acad Audiol 1992, 3(6):397-404.
17. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ: High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992, 165(6):1026-1032.
18. Rizzi MD, Hirose K: Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 2007, 15(5):352-357.
19. Selimoglu E: Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007, 13(1):119-126.
20. Brummett RE, Fox KE: Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989, 33(6):797-800.
21. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH, Tugela Ferry Care and Research (TF CARES), et al: HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181(1):80-86.
22. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK: Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl JMed 1993, 328(16):1137-1144.
23. Zetola NM, Olabiyi B, Ramogola-Masire D, Modongo C: Measuring stigma: are we looking in the right places? Int J Tuberc Lung Dis 2012, 16(8):1130-1131.
24. Zetola NM, Modongo C, Kip EC, Gross R, Bisson GP, Collman RG: Alcohol use and abuse among patients with multidrug-resistant tuberculosis in Botswana. Int J Tuberc Lung Dis 2012, 16(11):1529-1534.
25. Modongo C, Zetola NM: Prevalence of hypothyroidism among MDR-TB patients in Botswana. Int J Tuberc Lung Dis 2012, 16(11):1561-1562.
26. Organization WH: 2011 Global Tuberculosis Control. In 2011:258.
27. Botswana Ministry of Health, Office of Statistics: Final report: Botswana AIDS Impact Survey III (BAIS III-2008). In Gaborone, Botswana: 2009.
28. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C: Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 2004, 42(5):2321-2325.
29. Madison B, Gross W, George I, Sloutsky A, Washabaugh G, Robinson-Dunn B, Lipman H, Metchock B, Mazurek G, Ridderhof J: Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002, 40(10):3753-3756.
30. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J: Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002, 40(11):3976-3979.
31. Government of Botswana MoH: 2012 Botswana National HIV & AIDS Treatment Guidelines. In Gaborone: 2012.
32. Organization WH: Definitions and reporting framework for tuberculosis-2013 revision. In 2013.
33. Nevins M, Bright M: Cockcroft-Gault formula for diagnosing moderate kidney failure. J Am Geriatr Soc 2008, 56(4):774.
34. Shoker A, Hossain MA, Koru-Sengul T, Raju DL, Cockcroft D: Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 2006, 66(2):89-97.
35. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P: Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16(3):763-773.
36. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005, 16(2):459-466.
37. Rastogi N, Labrousse V, Goh KS: In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996, 33(3):167-175.
38. de Jager P, van Altena R: Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002, 6(7):622-627.
39. Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ: Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J 2012, 102(6 Pt 2):363-366.
40. Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL: Ototoxicity of amikacin. Antimicrob Agents Chemother 1976, 9(6):956-961.
41. Barza M, Lauermann MW, Tally FP, Gorbach SL: Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity. Antimicrob Agents Chemother 1980, 17(4):707-714.
42. Govaerts PJ, Claes J, van de Heyning PH, Jorens PG, Marquet J, De Broe ME: Aminoglycoside-induced ototoxicity. Toxicol Lett 1990, 52(3):227-251.
43. Mills CD, Loos BM, Henley CM: Increased susceptibility of male rats to kanamycin-induced cochleotoxicity. Hear Res 1999, 128(1-2):75-79.
44. Wu WJ, Sha SH, McLaren JD, Kawamoto K, Raphael Y, Schacht J: Aminoglycoside ototoxicity in adult CBA, C57BL and BALB mice and the Sprague-Dawley rat. Hear Res 2001, 158(1-2):165-178.